Plasma GM-CSF levels were lower, and Krebs von den Lungen 6 and GM-CSF autoantibody ranges were higher, in patients with aPAP compared with other populations. The gene discussed is CSF2; the disease is autoimmune pulmonary alveolar proteinosis.